A recent article published in the BMJ compared elective induction with expectant management.
Advertisement
Elective induction of labor appears to be a safe option for pregnant women who are at term, thus reducing perinatal mortality and without an increased risk for cesarean sections.
On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Garima Sharma, MD, outlines validated cardiac risk scores for antenatal screening and the postpartum transitions needed to keep high-risk patients from being lost to follow-up.